
Medivation Announces Presentation of Phase I Talazoparib Combination Data in Several Advanced Cancers
Talazoparib in Combination With Low-Dose Chemotherapy Resulted in 57% Objective Responses in Heavily Pre-Treated Non-BRCA Ovarian Cancer Patients; Oral Presentation at American Association for Cancer Research Annual Meeting Note: This press release …